General AML,   NPM1,  FLT3

Dr. Jacob M. Rowe | EBMT 2018 | How do you recommend AML patients for transplantation in CR1?


Dr. Jacob M. Rowe (member of our European Steering Committee) from Shaare Zedek Medical Center, Jerusalem, IL, discusses recommendations for AML patients in CR1 for transplant at the 44th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, 18–21 Mar 2018, Lisbon, PT. He highlighted that the best treatment for any patient with AML in terms of preventing leukemia reoccurrence is an allogeneic stem cell transplant. 

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF